ADARx Pharmaceuticals Stock

adarx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $352.5MM

ADARx Pharmaceuticals is a company that specializes in genetic medicine designed to treat human diseases and ailments using mRNA transcripts. ADARx researches and develops its therapies through oligonucleotides delivery technology. The firm focuses on three main disease treatments: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases.

Register To Buy and Sell Shares

For more details on financing and valuation for ADARx Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access ADARx Pharmaceuticals’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like ADARx Pharmaceuticals.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Zhen Li Ph.D
Co-Founder, Chief Executive Officer & President
Christopher Prentiss
Chief Financial Officer
Robert MacLeod Ph.D
Chief Scientific Officer
Rui Zhu Ph.D
Co-Founder & Vice President, Research and Development

Board Members

Chen-Ming Yu MD
TCG Crossover Management
Erez Chimovits
Judith Li
Lilly Asia Ventures
Lorence Kim MD
Ascenta Capital
Ricky Sun Ph.D
Bain Capital Life Sciences
Simeon George MD
SR One Capital Management
Yuan Sun
Sirona Capital

Frequently Asked Questions About ADARx Pharmaceuticals’ Stock

Can you buy ADARx Pharmaceuticals’ stock?
ADARx Pharmaceuticals is not publicly traded on NYSE or NASDAQ in the U.S. To buy ADARx Pharmaceuticals’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell ADARx Pharmaceuticals’ stock?
Yes, you can sell stock of a private company like ADARx Pharmaceuticals. Forge can help you sell your ADARx Pharmaceuticals stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is ADARx Pharmaceuticals’ stock price?
ADARx Pharmaceuticals is a privately held company and therefore does not have a public stock price. However, you may access ADARx Pharmaceuticals’ private market stock price with Forge Data.
What is ADARx Pharmaceuticals’ stock ticker symbol?
ADARx Pharmaceuticals does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

RNA biotech ADARx hauls in $200M, almost doubling 2 previous raises combined
Who says crossover rounds are dying? ADARx has raked in a $200 million series C, almost twice as much as the previous two joint series B rounds combined. The question now is, how quickly can the biotech's RNA pipeline be expanded?
San Diego biotech lands $46M for treatment targeting life-threatening swelling attacks
ADARx Pharmaceuticals is working on an RNA precision medicine platform spanning multiple therapeutic areas.
Updated on: Feb 27, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.